|1.||Sternberg, Cora N: 1 article (01/2013)|
|2.||Le-Guennec, Solenn: 1 article (01/2013)|
|3.||Bellmunt, Joaquim: 1 article (01/2013)|
|4.||Castellano, Daniel: 1 article (01/2013)|
|5.||Machiels, Jean-Pascal: 1 article (01/2013)|
|6.||Cerbone, Linda: 1 article (01/2013)|
|7.||Theodore, Christine: 1 article (01/2013)|
|8.||Peters, Frank: 1 article (01/2013)|
|9.||Blais, Normand: 1 article (01/2013)|
|10.||Risse, Marie-Laure: 1 article (01/2013)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/2010 - "This primary objective of this phase I dose-escalation study was to define the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of larotaxel administered in combination with carboplatin in chemotherapy-naïve patients with advanced/metastatic non-small cell lung cancer (NSCLC). "
01/01/2010 - "A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer."
08/01/2008 - "Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer."
08/01/2008 - "This randomized phase II study investigated the efficacy and safety of a new taxane, larotaxel (XRP9881), in combination with either cisplatin or gemcitabine in the first-line treatment of patients with nonirradiable stage IIIB or stage IV non-small cell lung cancer to select the combination having the most promising antitumor activity. "
|2.||Urinary Bladder Neoplasms (Bladder Cancer)
01/01/2013 - "Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)."
01/01/2013 - "This open-label, randomized phase III trial evaluated larotaxel/cisplatin versus gemcitabine/cisplatin as first-line treatment for locally advanced (T4b) or metastatic urothelial tract or bladder cancer. "
|3.||Breast Neoplasms (Breast Cancer)
07/01/2008 - "Larotaxel (XRP9881) is a novel taxoid with preclinical activity against taxane-resistant breast cancer. "
07/01/2008 - "Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy."
12/01/2009 - "Larotaxel (XRP9881, RPR109881), a novel semi-synthetic taxoid that shares a mode of action with the taxanes docetaxel and paclitaxel, was active in preclinical studies against a broad spectrum of tumour cells and tumour models refractory/resistant to taxanes, and have demonstrated clinical activity in taxane pre-treated/resistant metastatic breast cancer (MBC) patients. "
01/01/2010 - "The MTD of the combination was defined as larotaxel 60 mg/m(2) with a carboplatin AUC of 6 mg/mL × min. Neutropenia, reported at grade 3/4 in 15/18 patients (83%), was the most common severe adverse event, reaching grade 4 in 14 patients (78%). "
04/01/2012 - "Other emerging microtubule targeted agents, such as vinflunine and larotaxel, also reported efficacy in patients with MBC who had received prior chemotherapy, with grade 3/4 neutropenia being the most common AEs for both agents. "
|1.||Drug Therapy (Chemotherapy)